REGENXBIO Inc, a clinical-stage biotechnology company, provides gene therapy product candidates to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. Its gene therapy product candidates are based on NAV Technology Platform, a proprietary adeno-associated virus (AAV) gene delivery platform.
Read More…
Industry, Sector and Symbol
Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Phone240-552-8181
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$218.51 million
Profitability
Miscellaneous
Employees192
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
Regenxbio (NASDAQ:RGNX) Frequently Asked Questions
What is Regenxbio's stock symbol?
Regenxbio trades on the NASDAQ under the ticker symbol "RGNX."
How were Regenxbio's earnings last quarter?
Regenxbio Inc (NASDAQ:RGNX) announced its earnings results on Wednesday, August, 7th. The biotechnology company reported ($0.04) EPS for the quarter, topping the consensus estimate of ($0.50) by $0.46. The biotechnology company earned $7.88 million during the quarter, compared to analysts' expectations of $5.45 million. Regenxbio had a negative net margin of 88.57% and a negative return on equity of 15.39%. The business's revenue for the quarter was down 80.3% on a year-over-year basis. During the same period last year, the company posted $0.30 earnings per share. View Regenxbio's Earnings History.
When is Regenxbio's next earnings date?
What price target have analysts set for RGNX?
8 brokerages have issued twelve-month target prices for Regenxbio's stock. Their predictions range from $37.00 to $150.00. On average, they expect Regenxbio's share price to reach $79.13 in the next year. This suggests a possible upside of 106.1% from the stock's current price. View Analyst Price Targets for Regenxbio.
What is the consensus analysts' recommendation for Regenxbio?
8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Regenxbio in the last year. There are currently 3 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Regenxbio.
What are Wall Street analysts saying about Regenxbio stock?
Here are some recent quotes from research analysts about Regenxbio stock:
- 1. According to Zacks Investment Research, "REGENXBIO Inc. is a biotechnology company. The Company focuses on the development, commercialization and licensing of recombinant adeno-associated virus gene therapy. Its products candidates include RGX-501, for the treatment of homozygous familial hypercholesterolemia which uses the AAV8 vector to deliver the human low-density lipoprotein receptor gene to liver cells; RGX-111, for the treatment of Mucopolysaccharidosis Type I which uses the AAV9 vector to deliver the human a-l-iduronidase gene to the central nervous system; RGX-121, for the treatment of Mucopolysaccharidosis Type II; RGX-314, for the treatment of wet age-related macular degeneration and RGX-321, for the treatment of X-linked retinitis pigmentosa. REGENXBIO Inc. is headquartered in Rockville, Maryland. " (10/16/2019)
- 2. Chardan Capital analysts commented, "We note Sarepta Therapeutics (unrated) may be relevant for that theme. The IP discussion began by REGENXBIO discussing Zolgensma and the agreement with Avexis, a Novartis (unrated) company, where REGENXBIO will receive tiered royalties of 6%, 8%, and 10% on Zolgensma sales of $600 mm, respectively, as well as a milestone payment of $80 mm once Zolgensma reaches $1 bn in aggregate sales." (6/18/2019)
Has Regenxbio been receiving favorable news coverage?
Media headlines about RGNX stock have been trending negative on Wednesday, InfoTrie Sentiment reports. The research group identifies negative and positive press coverage by reviewing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Regenxbio earned a coverage optimism score of -2.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent press coverage is extremely likely to have an impact on the stock's share price in the next several days. View News Stories for Regenxbio.
Are investors shorting Regenxbio?
Regenxbio saw a increase in short interest in September. As of September 30th, there was short interest totalling 4,170,000 shares, an increase of 15.5% from the August 30th total of 3,610,000 shares. Based on an average daily volume of 564,400 shares, the short-interest ratio is currently 7.4 days. Approximately 12.6% of the company's stock are short sold. View Regenxbio's Current Options Chain.
Who are some of Regenxbio's key competitors?
Some companies that are related to Regenxbio include Moderna (MRNA), bluebird bio (BLUE), China Biologic Products (CBPO), argenx (ARGX), Repligen (RGEN), Spark Therapeutics (ONCE), Ablynx (ABLYF), BioNTech (BNTX), Allogene Therapeutics (ALLO), Adaptive Biotechnologies (ADPT), Iovance Biotherapeutics (IOVA), Halozyme Therapeutics (HALO), Acceleron Pharma (XLRN), Crispr Therapeutics (CRSP) and Denali Therapeutics (DNLI).
What other stocks do shareholders of Regenxbio own?
Who are Regenxbio's key executives?
Regenxbio's management team includes the folowing people:
- Mr. Kenneth T. Mills, CEO, Pres & Director (Age 44)
- Mr. Vittal K. Vasista, Chief Financial Officer (Age 51)
- Mr. Curran M. Simpson, Sr. VP of Product Devel. & Chief Technology Officer (Age 57)
- Dr. Olivier Danos, Chief Scientific Officer (Age 61)
- Dr. Stephen Yoo, Consultant (Age 41)
Who are Regenxbio's major shareholders?
Regenxbio's stock is owned by a variety of of institutional and retail investors. Top institutional investors include State of Alaska Department of Revenue (0.07%) and NEXT Financial Group Inc (0.01%). Company insiders that own Regenxbio stock include Curran Simpson, Donald J Hayden Jr, Kenneth T Mills, Luke M Beshar, Olivier Danos, Patrick J Christmas, Stephen Yoo and Vittal Vasista. View Institutional Ownership Trends for Regenxbio.
Which institutional investors are buying Regenxbio stock?
How do I buy shares of Regenxbio?
Shares of RGNX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is Regenxbio's stock price today?
One share of RGNX stock can currently be purchased for approximately $38.40.
How big of a company is Regenxbio?
Regenxbio has a market capitalization of $1.41 billion and generates $218.51 million in revenue each year. The biotechnology company earns $99.94 million in net income (profit) each year or $2.38 on an earnings per share basis. Regenxbio employs 192 workers across the globe.View Additional Information About Regenxbio.
What is Regenxbio's official website?
How can I contact Regenxbio?
Regenxbio's mailing address is 9600 BLACKWELL ROAD SUITE 210, ROCKVILLE MD, 20850. The biotechnology company can be reached via phone at 240-552-8181 or via email at [email protected]
MarketBeat Community Rating for Regenxbio (NASDAQ RGNX)
MarketBeat's community ratings are surveys of what our community members think about Regenxbio and other stocks. Vote "Outperform" if you believe RGNX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RGNX will underperform the S&P 500 over the long term. You may vote once every thirty days.
